{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:30:14Z","timestamp":1759332614772},"reference-count":93,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.amepre.2015.09.007","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T00:01:54Z","timestamp":1447804914000},"page":"S345-S354","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S4","title":["Vaccines for Prevention of Group B Meningococcal Disease"],"prefix":"10.1016","volume":"49","author":[{"given":"Lee H.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amepre.2015.09.007_bib0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1128\/MMBR.00056-12","article-title":"Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease","volume":"77","author":"McNeil","year":"2013","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.amepre.2015.09.007_bib0010","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1473-3099(13)70341-4","article-title":"A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/14712598.2015.983897","article-title":"The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy","volume":"15","author":"Rollier","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.amepre.2015.09.007_bib0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.amepre.2015.09.007_bib0025","doi-asserted-by":"crossref","first-page":"e979","DOI":"10.1542\/peds.2006-0281","article-title":"Multicenter surveillance of invasive meningococcal infections in children","volume":"118","author":"Kaplan","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.amepre.2015.09.007_bib0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0035","series-title":"Presentation to the Advisory Committee on Immunization Practices","article-title":"Epidemiology of serogroup B meningococcal disease, United States","author":"MacNeil","year":"2014"},{"key":"10.1016\/j.amepre.2015.09.007_bib0040","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(07)70288-8","article-title":"Meningococcal carriage in the African meningitis belt","volume":"7","author":"Trotter","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0045","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0050","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3201\/eid1206.051297","article-title":"Social behavior and meningococcal carriage in British teenagers","volume":"12","author":"MacLennan","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0055","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/infdis\/jiu679","article-title":"Meningococcal carriage among georgia and Maryland high school students","volume":"211","author":"Harrison","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/341067","article-title":"Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease","volume":"186","author":"Kellerman","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0065","first-page":"1","article-title":"Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.amepre.2015.09.007_bib0070","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0075","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1542\/peds.2014-2035","article-title":"Epidemiology of infant meningococcal disease in the United States, 2006\u20132012","volume":"135","author":"MacNeil","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.amepre.2015.09.007_bib0080","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.281.20.1906","article-title":"Risk of meningococcal infection in college students","volume":"281","author":"Harrison","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2015.09.007_bib0085","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jama.286.6.688","article-title":"Risk factors for meningococcal disease in college students","volume":"286","author":"Bruce","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2015.09.007_bib0090","first-page":"13","article-title":"Meningococcal disease and college students. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.amepre.2015.09.007_bib0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/504804","article-title":"Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994\u20132002","volume":"43","author":"Brooks","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0100","series-title":"Presentation to the Advisory Committee on Immunization Practices","article-title":"Epidemiology of meningococcal disease outbreaks in the United States","author":"Meyer","year":"2014"},{"key":"10.1016\/j.amepre.2015.09.007_bib0105","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","article-title":"Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines","volume":"30","author":"Ladhani","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2015.09.007_bib0110","first-page":"E224","article-title":"Australian Meningococcal Surveillance Programme annual report, 2012","volume":"37","author":"Lahra","year":"2013","journal-title":"Commun Dis Intell Q Rep"},{"key":"10.1016\/j.amepre.2015.09.007_bib0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1128\/CMR.19.1.142-164.2006","article-title":"Prospects for vaccine prevention of meningococcal infection","volume":"19","author":"Harrison","year":"2006","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.amepre.2015.09.007_bib0120","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.amepre.2015.09.007_bib0125","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2015.09.007_bib0130","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.amepre.2015.09.007_bib0135","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/cid\/ciu597","article-title":"The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012","volume":"59","author":"Sadarangani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bjid.2013.11.012","article-title":"Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil","volume":"18","author":"Tauil Mde","year":"2014","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0145","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.amepre.2015.09.007_bib0150","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1473-3099(12)70168-8","article-title":"Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data","volume":"12","author":"Novak","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.amepre.2015.09.007_bib0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3201\/eid2101.140256","article-title":"Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013","volume":"21","author":"Gamougam","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0165","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0170","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amepre.2015.09.007_bib0175","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0180","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0185","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.amepre.2015.09.007_bib0190","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amepre.2015.09.007_bib0195","series-title":"Vaccines","first-page":"388","article-title":"Meningococcal vaccines","author":"Granoff","year":"2013"},{"key":"10.1016\/j.amepre.2015.09.007_bib0200","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1086\/315833","article-title":"Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992\u20131998","volume":"182","author":"Sacchi","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0205","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/651505","article-title":"Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000\u20132005","volume":"201","author":"Harrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0210","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"issue":"Suppl. 5","key":"10.1016\/j.amepre.2015.09.007_bib0215","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1469-0691.2012.03939.x","article-title":"Developing vaccines in the era of genomics: a decade of reverse vaccinology","volume":"18","author":"Seib","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.amepre.2015.09.007_bib0220","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZBtrade mark: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2015.09.007_bib0225","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection-serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2015.09.007_bib0230","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.vaccine.2009.12.027","article-title":"Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates","volume":"28","author":"Pajon","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2015.09.007_bib0235","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","article-title":"Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2015.09.007_bib0240","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2015.09.007_bib0245","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2015.09.007_bib0250","doi-asserted-by":"crossref","first-page":"e50659","DOI":"10.1371\/journal.pone.0050659","article-title":"The changing epidemiology of meningococcal disease in Quebec, Canada, 1991\u20132011: potential implications of emergence of new strains","volume":"7","author":"Gilca","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.amepre.2015.09.007_bib0255","unstructured":"Agence de la Sant\u00e9 et des Services Sociaux du Saguenay \u2013 Lac-Saint-Jean Qu\u00e9bec. Premi\u00e8re vague de vaccination contre le m\u00e9ningocoque de s\u00e9rogroupe B. Available from www.csrsaguenay.qc.ca\/medias\/csrsaguenay\/fichiers\/Actualite\/Communique_fin_campagne_printemps_140618_3.pdf (accessed 19.06.14)."},{"key":"10.1016\/j.amepre.2015.09.007_bib0260","unstructured":"Agence de la Sant\u00e9 et des Services Sociaux du Saguenay \u2013 Lac-Saint-Jean Qu\u00e9bec. Targeted Meningococcal Serogroup B Vaccination Campaign in the Saguenay \u2013 Lac-Saint-Jean Region. www.msss.gouv.qc.ca\/sujets\/santepub\/vaccination\/index.php?meningococcal-b-vaccination-campaign, 2014."},{"key":"10.1016\/j.amepre.2015.09.007_bib0265","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2014-4015","article-title":"First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak","volume":"135","author":"McNamara","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.amepre.2015.09.007_bib0270","first-page":"606","article-title":"Serogroup B meningococcal disease outbreak and carriage evaluation at a college \u2013 Rhode Island, 2015","volume":"64","author":"Soeters","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amepre.2015.09.007_bib0275","unstructured":"Joint Committee on Vaccination and Immunisation. JCVI position statement on use of Bexsero\u00ae meningococcal B vaccine in the UK, March 2014. Available from www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/294245\/JCVI_Statement_on_MenB.pdf (accessed 21.03.14)."},{"key":"10.1016\/j.amepre.2015.09.007_bib0280","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amepre.2015.09.007_bib0285","first-page":"52","article-title":"Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amepre.2015.09.007_bib0290","first-page":"527","article-title":"Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013","volume":"63","author":"MacNeil","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amepre.2015.09.007_bib0295","unstructured":"Novartis. Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02212457 (accessed 19.01.15)."},{"issue":"March","key":"10.1016\/j.amepre.2015.09.007_bib0300","article-title":"A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2015.09.007_bib0305","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1016\/j.vaccine.2014.07.049","article-title":"A randomized, phase 1\/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants","volume":"32","author":"Martinon-Torres","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2015.09.007_bib0310","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.amepre.2015.09.007_bib0315","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amepre.2015.09.007_bib0320","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/2051013614557477","article-title":"Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection","volume":"3","author":"McIntosh","year":"2015","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.amepre.2015.09.007_bib0325","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.amepre.2015.09.007_bib0330","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0335","series-title":"International Pathogenic Neisseria Conference","article-title":"Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in United States","author":"Kim","year":"2012"},{"key":"10.1016\/j.amepre.2015.09.007_bib0340","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2015.09.007_bib0345","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/INF.0b013e31827b0d24","article-title":"A randomized, controlled, phase 1\/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents","volume":"32","author":"Nissen","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.amepre.2015.09.007_bib0350","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.amepre.2015.09.007_bib0355","first-page":"115","article-title":"Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics","volume":"122","author":"Stephens","year":"2011","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.amepre.2015.09.007_bib0360","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/501371","article-title":"Antigenic shift and increased incidence of meningococcal disease","volume":"193","author":"Harrison","year":"2006","journal-title":"J Infect Dis"},{"issue":"January","key":"10.1016\/j.amepre.2015.09.007_bib0365","article-title":"Changes in the population structure of invasive Neisseria meningitidis in the United States after quadrivalent meningococcal conjugate vaccine licensure","author":"Wang","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0370","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1086\/528996","article-title":"Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005","volume":"197","author":"Moore","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0375","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1128\/CVI.00717-13","article-title":"Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States","volume":"21","author":"Pawloski","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.amepre.2015.09.007_bib0380","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/cid\/ciu788","article-title":"Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage","volume":"60","author":"Martin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2015.09.007_bib0385","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/CVI.00055-11","article-title":"Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein","volume":"18","author":"Lucidarme","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.amepre.2015.09.007_bib0390","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1016\/j.vaccine.2013.06.009","article-title":"fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations","volume":"31","author":"Giuntini","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2015.09.007_bib0395","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1128\/IAI.01517-14","article-title":"Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model","volume":"82","author":"Lewis","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.amepre.2015.09.007_bib0400","series-title":"International Pathogenic Neisseria Conference","article-title":"Diversity of noncapsular antigens among Neisseria meningitidis isolates of serogroups C, W135 and Y in Brazil: implications for vaccine prevention","author":"Casti\u00f1eiras","year":"2012"},{"key":"10.1016\/j.amepre.2015.09.007_bib0405","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/JCM.02422-06","article-title":"Deletion of fetA gene sequences in serogroup B and C Neisseria meningitidis isolates","volume":"45","author":"Marsh","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.amepre.2015.09.007_bib0410","doi-asserted-by":"crossref","first-page":"e116024","DOI":"10.1371\/journal.pone.0116024","article-title":"Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero(R)) in Gipuzkoa, Northern Spain","volume":"9","author":"Perez-Trallero","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.amepre.2015.09.007_bib0415","first-page":"885","article-title":"National vaccination coverage among adolescents aged 13\u201317 years \u2013 United States, 2006","volume":"56","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amepre.2015.09.007_bib0420","first-page":"625","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years \u2013 United States, 2013","volume":"63","author":"Elam-Evans","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"July","key":"10.1016\/j.amepre.2015.09.007_bib0425","article-title":"The price of prevention: vaccine costs are soaring","author":"Rosenthal","year":"2014","journal-title":"The New York Times"},{"issue":"March","key":"10.1016\/j.amepre.2015.09.007_bib0430","article-title":"Pediatricians voice anger over costs of vaccines","author":"Pollack","year":"2007","journal-title":"The New York Times"},{"issue":"March","key":"10.1016\/j.amepre.2015.09.007_bib0435","article-title":"Now babies WILL get \u00a320 meningitis jab: after year-long row over cost, NHS gives it the nod","author":"Borland","year":"2015","journal-title":"Daily Mail"},{"key":"10.1016\/j.amepre.2015.09.007_bib0440","doi-asserted-by":"crossref","first-page":"g5725","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"Br Med J"},{"key":"10.1016\/j.amepre.2015.09.007_bib0445","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.1996.03540120045032","article-title":"Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule","volume":"276","author":"Miller","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2015.09.007_bib0450","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jama.1993.03500020055031","article-title":"Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era","volume":"269","author":"Adams","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2015.09.007_bib0455","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amepre.2015.09.007_bib0460","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa0800836","article-title":"Effect of pneumococcal conjugate vaccine on pneumococcal meningitis","volume":"360","author":"Hsu","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amepre.2015.09.007_bib0465","first-page":"220","article-title":"Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign","volume":"5","author":"Trotter","year":"2002","journal-title":"Commun Dis Public Health"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379715005462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379715005462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T08:43:34Z","timestamp":1556354614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379715005462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0749379715005462"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2015.09.007","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccines for Prevention of Group B Meningococcal Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2015.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}